BIOMERICA Business Summary

Biomerica Inc. (BMRA) is a biomedical technology firm that generates revenue through the development, manufacturing, and global marketing of advanced in-vitro diagnostic (IVD) products. The company is currently executing a strategic pivot from legacy, lower-margin screening tests toward high-value "diagnostic-guided therapy" (DGT) products, primarily targeting chronic gastrointestinal (GI) and inflammatory diseases. Its core revenue streams are derived from its patented inFoods IBS platform—which identifies patient-specific food triggers to manage Irritable Bowel Syndrome—as well as its hp+detect H. pylori tests and EZ Detect colorectal screening kits. Additionally, the company leverages its FDA-registered and ISO-certified facilities in California and Mexico to provide contract development and manufacturing organization (CDMO) services to multinational pharmaceutical and diagnostic partners. Biomerica competes directly with larger diagnostic players such as QuidelOrtho, Bio-Rad Laboratories, and Trinity Biotech; however, it maintains a specialized niche as a micro-cap innovator focused on personalized, non-invasive GI health solutions that bridge the gap between diagnostics and therapeutic dietary management. Originally founded in 1971 by Joseph H. Irani, the company is currently led by his son, Zackary "Zack" Irani, who has served as Chairman and CEO since 1997 and brings over four decades of experience within the firm. The executive leadership team includes CFO Gary Lu and Chief Commercial Officer Scott Madel, who joined in June 2025 with a background as President of Boston Heart Diagnostics to spearhead the commercial rollout of the inFoods platform. The Board of Directors is bolstered by significant industry pedigree, featuring Executive Vice Chairman Allen Barbieri, David Moatazedi (CEO of Evolus), and Dr. Jane Emerson (Vice Chair of Clinical Programs at USC Keck School of Medicine). Notable institutional support includes positions from Russell Investments, Geode Capital Management, and BlackRock, reflecting a stable investor base as the company pursues national Medicare reimbursement and expanded international distribution agreements.